期刊
MOLECULAR THERAPY-ONCOLYTICS
卷 18, 期 -, 页码 525-534出版社
CELL PRESS
DOI: 10.1016/j.omto.2020.08.006
关键词
-
资金
- Fundacion Universidad Alfonso X el Sabio, Madrid, Spain [1.010.909]
- Instituto de Salud Carlos III, Spain [PI14CIII/00005, PI17CIII/00013]
- Consejeria de Educacion, Juventud y Deporte, Comunidad de Madrid, Spain [P2017/BMD-3692]
- Fundacion Oncohematologia Infantil
- AFANION
- Asociacion Pablo Ugarte
Oncolytic immunotherapy with competent viruses is an emerging approach in cancer treatment. The clinical safety of many types of oncolytic viruses (OVs) has been demonstrated. However, there is a lack of information about viral biodistribution in patients. The available data about oncolytic adenovirus biodistribution in human subjects treated intravenously consists of virus detection in body fluids, a few tumor biopsies, and a single report of patient necropsy samples. There is no information about adenoviral biodistribution in patients treated intravenously with cellular vehicles carrying an oncolytic adenovirus. We previously published reports regarding the efficacy and clinical safety of infusing mesenchymal stem cells (MSCs) infected with an OV in human and canine patients. In this study, we performed necropsies on 12 canine patients treated with dCelyvir, canine MSCs infected with ICOCAV17, a canine oncolytic adenovirus. The prevalence of microscopic lesions, especially chronic inflammatory responses in different organs, was higher than expected. Concomitantly, we found a positive immunoreaction to ICOCAV17 in analyzed samples. These findings support a possible role of the virus in development of histopathological alterations and ongoing systemic viral replication of ICOCAV17 in the period after therapy administration.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据